Aesica has plans to grow and expand following a significant investment from Silverfleet Capital, a European private equity firm. Silverfleet Capital has agreed to a majority investment in Aesica and members of Aesica have reinvested for a large minority stake in the company.

The investment will allow Aesica to continue its expansion into new markets and grow its position as a major supplier of APIs and Formulated Products to the global pharmaceutical industry. Aesica has six manufacturing sites across Europe and sales representation across the U.S., Europe and Asia, and plans to extend its current capabilities and global manufacturing facilities.

Dr. Robert Hardy, chief executive officer of Aesica said, “We have known the team at Silverfleet Capital for a number of years and chose them as our financial partner because of their deep knowledge of our market and their experience and successful track record of building global businesses of scale through buy and build strategies. Our long term strategic plan was to establish a manufacturing presence in the U.S. and Asia in 2012 and with the support from Silverfleet Capital we can continue to expand into new markets, evolve and grow more swiftly.”